
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    Okay, I will proceed with the cell type annotation for a cluster from a human lung scRNA-seq dataset based on the provided ranked marker list: CD14, CD68, CD163.<br><br>### Step 1: Analyze Marker Genes<br><br>*   **CD14 (Cluster of Differentiation 14):** This is a well-established and highly specific marker for monocytes and macrophages. It acts as a co-receptor for Toll-like receptor 4 (TLR4) and is crucial for the innate immune response. In the context of scRNA-seq, high expression of CD14 is a strong indicator of myeloid lineage cells, particularly monocytes and certain macrophage populations.<br>*   **CD68 (Cluster of Differentiation 68):** Also known as macrosialin, CD68 is a transmembrane glycoprotein highly expressed by macrophages and other phagocytic cells. It is localized in lysosomes and endosomes and is involved in antigen processing and presentation. CD68 is a pan-macrophage marker, often used to identify cells of the monocyte-macrophage lineage.<br>*   **CD163 (Cluster of Differentiation 163):** This is a scavenger receptor primarily expressed on monocytes and macrophages, particularly those with an anti-inflammatory or M2-like phenotype. CD163 is involved in the clearance of hemoglobin-haptoglobin complexes and is often associated with tissue-resident macrophages and alternatively activated macrophages. Its presence, especially alongside CD14 and CD68, strongly points towards a specific macrophage subtype.<br><br>The ranking (CD14, CD68, CD163) suggests that CD14 is the most highly expressed, followed by CD68, and then CD163. This order is consistent with a myeloid cell type, specifically leaning towards monocytes or macrophages.<br><br>### Step 2: Consider Biological Context<br><br>*   **Tissue Type: Human Lung:** The lung is a highly vascularized and immunologically active organ. It contains a diverse population of immune cells, including a significant number of tissue-resident macrophages (alveolar macrophages being a prominent example) and circulating monocytes that can infiltrate the tissue and differentiate into macrophages.<br>*   **Species: Human:** The marker genes are well-characterized in human immunology, and their roles are consistent with known human cell biology.<br>*   **Biological Plausibility:** The presence of monocytes and macrophages in the lung is entirely expected and crucial for lung homeostasis, host defense, and inflammation resolution.<br><br>### Step 3: Formulate Hypotheses<br><br>Based on the strong myeloid markers, particularly those associated with phagocytic cells, I formulate the following hypotheses:<br><br>1.  **Hypothesis 1 (Most Likely): Macrophages (specifically, a monocyte-derived or tissue-resident macrophage population):** The co-expression of CD14, CD68, and CD163 is highly characteristic of macrophages. The presence of CD14, while often associated with classical monocytes, is also expressed by certain macrophage populations, especially those recently derived from monocytes or those with specific activation states. CD68 is a general macrophage marker, and CD163 points towards an M2-like or anti-inflammatory phenotype, which is common for tissue-resident macrophages or macrophages involved in resolving inflammation.<br>2.  **Hypothesis 2 (Less Likely, but possible as a precursor/related cell): Monocytes:** While monocytes express CD14 and CD68, CD163 expression is typically lower or induced upon differentiation into macrophages. Given the presence of CD163, it's more likely these cells have differentiated beyond a classical monocyte state, or represent a specific monocyte subset poised for differentiation. However, circulating monocytes can be captured in lung tissue samples.<br>3.  **Hypothesis 3 (Least Likely): Dendritic Cells (DCs):** While some DC subsets can express CD14 (e.g., monocyte-derived DCs), the strong co-expression of CD68 and CD163 makes DCs less likely as the primary identity. DCs have more specific markers (e.g., CD1c, CD141, CD103, CD11c, MHC-II high) that are not listed here.<br><br>**Ranking of Hypotheses by Likelihood:**<br>1.  Macrophages (specifically, a monocyte-derived or tissue-resident macrophage population, potentially with an M2-like phenotype)<br>2.  Monocytes (potentially differentiating or specific subsets)<br>3.  Dendritic Cells (unlikely)<br><br>### Step 4: Final Decision<br><br>**Definitive Cell Type Identification: Macrophages**<br><br>**Supporting Evidence:**<br>*   **CD14:** While a classical monocyte marker, CD14 is also expressed by various macrophage populations, particularly those recently recruited or with specific activation states. Its high expression here suggests a myeloid cell.<br>*   **CD68:** This is a robust and widely accepted pan-macrophage marker. Its presence strongly confirms the macrophage lineage.<br>*   **CD163:** This marker is highly specific for monocytes and macrophages, particularly those with an anti-inflammatory (M2-like) phenotype or involved in tissue remodeling and resolution of inflammation. Its co-expression with CD14 and CD68 is a hallmark of these macrophage subsets.<br><br>The combination of these three markers, especially with CD163, points overwhelmingly to a macrophage population. The high expression of CD14 suggests either a monocyte-derived macrophage population or a specific subset of tissue-resident macrophages that retain CD14 expression. The lung is rich in such cells, including alveolar macrophages and interstitial macrophages.<br><br>### Step 5: Consider Subtypes and Mixed Populations<br><br>*   **Relevant Subtypes/States:** Given the presence of CD163, this cluster likely represents **M2-like macrophages** or **tissue-resident macrophages** (e.g., interstitial macrophages) that have adopted an anti-inflammatory or reparative phenotype. It could also include **monocyte-derived macrophages** that have recently infiltrated the lung and are differentiating. Alveolar macrophages, while also macrophages, typically have a distinct marker profile (e.g., high CD206, CD169, MARCO, lower CD14). The strong CD14 expression here makes it less likely to be *pure* classical alveolar macrophages, but rather a population that includes interstitial macrophages or recently recruited monocyte-derived macrophages.<br>*   **Mixed Population:** It is possible this cluster contains a continuum of differentiation from monocytes to mature macrophages, or a mixture of closely related macrophage subsets (e.g., recently recruited monocyte-derived macrophages and a subset of interstitial macrophages). However, the consistent expression of these three markers suggests a relatively homogeneous population within the broader macrophage lineage.<br>*   **Confidence Level:** **High Confidence.** The marker combination (CD14, CD68, CD163) is highly specific and well-validated for identifying macrophages, particularly those with an M2-like or anti-inflammatory phenotype, in human tissues.<br><br>FINAL ANNOTATION COMPLETED<br>**Final Cell Type Annotation: Macrophages (likely M2-like or monocyte-derived/interstitial macrophages)**
                </div>
            
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">98</div>
                        <div class="scoring-content">
                            The single-cell annotation for the given cluster from human lung tissue, based on the ranked marker list (CD14, CD68, CD163), is exceptionally well-reasoned and scientifically accurate.<br><br>**Strengths:**<br><br>1.  **Thorough Marker Gene Analysis:** The analysis of each marker (CD14, CD68, CD163) is detailed, accurate, and provides relevant biological context for each. It correctly identifies the general role of each marker and its specificity within the immune system.<br>2.  **Consideration of Marker Rank:** The annotation explicitly acknowledges the ranking (CD14 > CD68 > CD163) and integrates this into the interpretation, noting that "This order is consistent with a myeloid cell type, specifically leaning towards monocytes or macrophages." This demonstrates a good understanding of how marker expression levels can inform cell identity.<br>3.  **Comprehensive Biological Context:** The annotation correctly incorporates the tissue origin (human lung) and species (human) into the analysis, recognizing the expected presence of immune cells, particularly macrophages, in this organ.<br>4.  **Well-Formulated Hypotheses:** The generation of multiple hypotheses (Macrophages, Monocytes, Dendritic Cells) and their subsequent ranking based on likelihood is a robust approach. This shows a systematic evaluation process rather than jumping to an immediate conclusion.<br>5.  **Strong Justification for Final Annotation:** The definitive annotation of "Macrophages (likely M2-like or monocyte-derived/interstitial macrophages)" is strongly supported by the co-expression of all three markers. The explanation correctly highlights that CD68 is a pan-macrophage marker and CD163 points towards an M2-like phenotype, which is crucial for refining the macrophage identity.<br>6.  **Nuance in Macrophage Subtyping:** The discussion about the implications of CD14 presence (monocyte-derived vs. tissue-resident, not classical alveolar macrophages) and the suggestion of M2-like or interstitial macrophages demonstrates a deep understanding of macrophage heterogeneity within the lung. This moves beyond a simple "macrophage" label to a more specific and biologically plausible subtype.<br>7.  **Consideration of Mixed Populations/Continuum:** The acknowledgment that the cluster might represent a continuum of differentiation or a mixture of closely related macrophage subsets adds a layer of sophistication and realism to the annotation, reflecting the complexity often seen in scRNA-seq data.<br>8.  **High Confidence Justification:** The stated "High Confidence" is well-justified given the strong and consistent expression of established myeloid/macrophage markers.<br>9.  **Clear and Logical Flow:** The step-by-step process (Analyze Markers, Biological Context, Hypotheses, Final Decision, Subtypes) is easy to follow and demonstrates a logical thought process.<br><br>**Weaknesses/Areas for Minor Improvement (very minor):**<br><br>1.  **Elaboration on CD14 in Macrophages:** While the annotation correctly states that CD14 is expressed by various macrophage populations, a slightly deeper dive into *why* CD14 might be highly expressed in a macrophage cluster (e.g., recent monocyte egress, specific inflammatory states, certain tissue-resident populations) would further strengthen this point. However, this is already implicitly covered by suggesting "monocyte-derived" macrophages.<br><br>Overall, the annotation demonstrates an expert-level understanding of immunology, single-cell data interpretation, and the specific markers provided. It successfully captures the overall picture of the data, provides a highly accurate and nuanced cell type identification, and articulates its reasoning clearly and comprehensively.
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    